Literature DB >> 20416366

Towards preserving the immunogenicity of protein antigens carried by nanoparticles while avoiding the cold chain.

Brian R Sloat1, Michael A Sandoval, Zhengrong Cui.   

Abstract

Nanoparticles are an attractive vaccine carrier with potent adjuvant activity. Data from our previous studies showed that immunization of mice with lecithin/glyceryl monostearate-based nanoparticles with protein antigens conjugated onto their surface induced a strong, quick, and long-lasting antigen-specific immune response. In the present study, we evaluated the feasibility of preserving the immunogenicity of protein antigens carried by nanoparticles without refrigeration using these antigen-conjugated nanoparticles as a model. The nanoparticles were lyophilized, and the immunogenicity of the antigens was evaluated in a mouse model using bovine serum albumin or the Bacillus anthracis protective antigen protein as model antigens. With proper excipients, the nanoparticles can be lyophilized while maintaining the immunogenicity of the antigens. Moreover, the immunogenicity of the model antigen conjugated onto the nanoparticles was undamaged after a relatively extended period of storage at room temperature or under accelerated conditions (37 degrees C) when the nanoparticles were lyophilized with 5% mannitol plus 1% polyvinylpyrrolidone. To our knowledge, the present study represents an early attempt to preserve the immunogenicity of the protein antigens carried by nanoparticles without refrigeration. 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20416366      PMCID: PMC2893573          DOI: 10.1016/j.ijpharm.2010.04.003

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  18 in total

Review 1.  Lyophilization and development of solid protein pharmaceuticals.

Authors:  W Wang
Journal:  Int J Pharm       Date:  2000-08-10       Impact factor: 5.875

2.  Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases.

Authors:  Zhengrong Cui; Paul R Lockman; Craig S Atwood; Cheng-Hsuan Hsu; Anshul Gupte; David D Allen; Russell J Mumper
Journal:  Eur J Pharm Biopharm       Date:  2005-02       Impact factor: 5.571

Review 3.  Recombinant subunit vaccines: potentials and constraints.

Authors:  T G Clark; D Cassidy-Hanley
Journal:  Dev Biol (Basel)       Date:  2005

4.  The effects of formulation and moisture on the stability of a freeze-dried monoclonal antibody-vinca conjugate: a test of the WLF glass transition theory.

Authors:  M L Roy; M J Pikal; E C Rickard; A M Maloney
Journal:  Dev Biol Stand       Date:  1992

5.  The physical state of mannitol after freeze-drying: effects of mannitol concentration, freezing rate, and a noncrystallizing cosolute.

Authors:  A I Kim; M J Akers; S L Nail
Journal:  J Pharm Sci       Date:  1998-08       Impact factor: 3.534

Review 6.  The role of vitrification in anhydrobiosis.

Authors:  J H Crowe; J F Carpenter; L M Crowe
Journal:  Annu Rev Physiol       Date:  1998       Impact factor: 19.318

7.  Physical factors affecting the storage stability of freeze-dried interleukin-1 receptor antagonist: glass transition and protein conformation.

Authors:  B S Chang; R M Beauvais; A Dong; J F Carpenter
Journal:  Arch Biochem Biophys       Date:  1996-07-15       Impact factor: 4.013

Review 8.  Rational design of stable lyophilized protein formulations: some practical advice.

Authors:  J F Carpenter; M J Pikal; B S Chang; T W Randolph
Journal:  Pharm Res       Date:  1997-08       Impact factor: 4.200

9.  Lecithin-based cationic nanoparticles as a potential DNA delivery system.

Authors:  Zhengrong Cui; Fu Qiu; Brian R Sloat
Journal:  Int J Pharm       Date:  2006-02-23       Impact factor: 5.875

10.  Strong antibody responses induced by protein antigens conjugated onto the surface of lecithin-based nanoparticles.

Authors:  Brian R Sloat; Michael A Sandoval; Andrew M Hau; Yongqun He; Zhengrong Cui
Journal:  J Control Release       Date:  2009-09-01       Impact factor: 9.776

View more
  8 in total

1.  Induction of protective neutralizing antibody responses against botulinum neurotoxin serotype C using plasmid carried by PLGA nanoparticles.

Authors:  Tinashe B Ruwona; Haiyue Xu; Junwei Li; Diana Diaz-Arévalo; Amit Kumar; Mingtao Zeng; Zhengrong Cui
Journal:  Hum Vaccin Immunother       Date:  2016-02-02       Impact factor: 3.452

2.  Relationship between the size of nanoparticles and their adjuvant activity: data from a study with an improved experimental design.

Authors:  Xinran Li; Brian R Sloat; Nijaporn Yanasarn; Zhengrong Cui
Journal:  Eur J Pharm Biopharm       Date:  2010-12-21       Impact factor: 5.571

3.  Tresyl-based conjugation of protein antigen to lipid nanoparticles increases antigen immunogenicity.

Authors:  Anekant Jain; Weili Yan; Keith R Miller; Ronan O'Carra; Jerold G Woodward; Russell J Mumper
Journal:  Int J Pharm       Date:  2010-09-15       Impact factor: 5.875

Review 4.  Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses.

Authors:  Moses O Oyewumi; Amit Kumar; Zhengrong Cui
Journal:  Expert Rev Vaccines       Date:  2010-09       Impact factor: 5.217

5.  Microneedle-mediated transcutaneous immunization with plasmid DNA coated on cationic PLGA nanoparticles.

Authors:  Amit Kumar; Piyanuch Wonganan; Michael A Sandoval; Xinran Li; Saijie Zhu; Zhengrong Cui
Journal:  J Control Release       Date:  2012-08-19       Impact factor: 9.776

6.  Permeation of antigen protein-conjugated nanoparticles and live bacteria through microneedle-treated mouse skin.

Authors:  Amit Kumar; Xinran Li; Michael A Sandoval; B Leticia Rodriguez; Brian R Sloat; Zhengrong Cui
Journal:  Int J Nanomedicine       Date:  2011-06-21

7.  A polymer/oil based nanovaccine as a single-dose immunization approach.

Authors:  Sara Vicente; Belen Diaz-Freitas; Mercedes Peleteiro; Alejandro Sanchez; David W Pascual; Africa Gonzalez-Fernandez; Maria J Alonso
Journal:  PLoS One       Date:  2013-04-22       Impact factor: 3.240

Review 8.  Development of thermostable vaccine adjuvants.

Authors:  Yizhi Qi; Christopher B Fox
Journal:  Expert Rev Vaccines       Date:  2021-06-26       Impact factor: 5.683

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.